Irritable Bowel Syndrome

In an international survey, investigators discover women are more likely to suffer from a FGID than men.

In a new study, investigators discover fewer adverse events in patients taking 1 × 109 non-viable B bifidum HI-MIMBb75 cells than for patients taking a placebo.

The most common reason IBS patients discontinue treatment is a loss of prescription drug coverage.

A 28-day patient log of gastrointestinal symptoms, stool consistency, psychological distress, and extraintestinal pain ratings informs investigators on the significance of markers.

In a new study, investigators examine whether a low FODMAP diet could be beneficial for patients suffering from quiescent IBD.

In the last decade, investigators have put an emphasis on better disease monitoring for digestive diseases. The result has been better patient outcomes.

William Sandborn, MD, chief of the division of gastroenterology at University of California, San Diego, shares updates from ACG 2019 in the field of gastroenterology.

Stephen B. Hanauer, MD, discusses areas of unmet need in gastroenterology and shares what news made a splash at ACG 2019.

Brooks Cash, MD, delivers his take on areas of unmet need within the gastroenterology field.

From baseline to 12 weeks, all participants demonstrated a significant reduction in total percentage of abnormal bowel movements, overall IBS Symptom Severity Score, abdominal pain and bloating severity, and an improvement in health-related quality of life.

Ustekinumab (Stelara) has received approval from the US Food and Drug Administration for the treatment of moderate to severely active ulcerative colitis in adults.

The AGA-approved guidelines call for a variety of different testing to better diagnose IBS-D in adults.

The FDA-approved drug targets IBS-C patients by increasing bowel movements, while lowering abdominal pain.

In a new multivariable regression study, investigators link depression with a lack of social support and increased IBD activity.

New evidence from a cumulative RCT analysis suggests irritable bowel syndrome patients do not definitively benefit from FMT treatment.